2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsHumansLymphoma, Mantle-CellProgression-Free SurvivalRetrospective StudiesRisk AssessmentConceptsProgression-free survivalMantle cell lymphomaOverall survivalPleomorphic variantMedian progression-free survivalB-cell non-Hodgkin lymphomaOutcomes of patientsAutologous hematopoietic transplantationNon-Hodgkin lymphomaComplete responsePatient characteristicsPoor prognosisHematopoietic transplantationCell lymphomaSecondary objectiveMonthsPatientsLymphomaSurvivalHigher scoresPrimary objectivePrognosisTransplantationNeoplasmsHigh-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.Peer-Reviewed Original ResearchConceptsProgression-free survivalMulti-institutional retrospective studyHigh-grade B-cell lymphomaOverall survivalB-cell lymphomaComplete responseMYC rearrangementRetrospective studyBCL6 rearrangementsGerminal center B-cell immunophenotypeHigh serum lactate dehydrogenaseHigh-risk clinical factorsBetter progression-free survivalIntensive chemotherapy programsPoor performance statusStage IV diseaseFirst-line regimensMain prognostic factorsDose-intense chemotherapyHigh-grade morphologic featuresSerum lactate dehydrogenaseB-cell immunophenotypeDA-EPOCHR-CHOPMost patientsOptimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. The Oncologist 2023, 28: 246-251. PMID: 36651837, PMCID: PMC10020806, DOI: 10.1093/oncolo/oyac245.Peer-Reviewed Original ResearchMeSH KeywordsBone and BonesBone NeoplasmsHumansMaleProstatic Neoplasms, Castration-ResistantRadiumRetrospective StudiesConceptsBaseline BSIBone scan indexMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerOverall survivalSkeletal metastasesRa-223 therapyRa-223 treatmentRadium-223 treatmentTreatment-associated reductionChemotherapy-naïve patientsMedian overall survivalAbsolute neutrophil countRadium-223 dichlorideHigh serum PSANovel treatment modalitiesAlkaline phosphatase levelsChemotherapy-naïveTreatment tolerabilityNeutrophil countSerum PSABone scanLaboratory parametersPatient selection
2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal Of Clinical Oncology 2019, 37: 471-480. PMID: 30615550, PMCID: PMC7554677, DOI: 10.1200/jco.18.00690.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Mantle-CellMaleMiddle AgedNorth AmericaProgression-Free SurvivalRetrospective StudiesRisk AssessmentRisk FactorsRituximabTime FactorsTransplantation, AutologousYoung AdultConceptsImproved progression-free survivalProgression-free survivalMantle cell lymphomaTransplantation-eligible patientsOverall survivalMultivariable regression analysisRituximab eraCell lymphomaLarge cohortMedian progression-free survivalPropensity score-weighted analysisAdults age 65 yearsImproved overall survivalAge 65 yearsB-cell lymphomaRegression analysisCyclin D1 expressionEligible patientsFit patientsImproved OSInduction chemotherapyYounger patientsSurvival outcomesUnadjusted analysesInclusion criteria